# Stribild® Registration In The Developing World

### **Approved**

1. Argentina	October 2013	3. Chile	December 2013	5. Haiti	May 2013
2. Aruba	September 2013	4. Costa Rica	March 2013	6. Jamaica	April 2014
Filed					

1. Bangladesh	September 2013	8. Mexico	April 2013	15. Trinidad and Tobago	July 2013
2. Bolivia	June 2013	9. Myanmar	September 2013	16. Uganda	July 2014
3. Colombia	April 2013	10. Pakistan	March 2014	17. Uruguay	August 2013
4. Curacao	June 2013	11. Paraguay	August 2013	18. Venezuela	June 2013
5. Ethiopia	March 2014	12. South Africa	May 2014	19. Zimbabwe	May 2014
6. Laos	April 2013	13. Tanzania	June 2014		
7. Malawi	April 2014	14. Thailand	May 2013		

## **Pending Submission**

1. Botswana	6. Ghana	11. Sudan	
2. Brazil	7. India (pending clinical trial waiver)	12. Vietnam	
3. Cameroon	8. Kenya	13. Zambia	
4. Congo, Dem. Rep. of the	9. Mozambique		
5. Côte d'Ivoire	10. Nigeria		

### **Terms and Definitions**

Approved: Dossier submitted and approved by country or no formal regulatory process in place; approval confirmed by country. Filed: Dossier submitted and review pending.

Pending Submission: Dossier has not been submitted to date; standard dossier filed - specific documentation required in order to further application process; or all relevant documentation provided to distributor for in-country submission (submission may be pending translation into local language).

There can be no guarantee that marketing approval for Stribild® will be granted in any of the low- and middle-income countries where registration is pending; any marketing approval, if granted, may have significant limitations on its use.

GILEAD

July 2014 www.gilead.com